Lipoic Acid as a Treatment for Acute Optic Neuritis

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if oral lipoic acid can safely help relieve permanent optic nerve injury in patients diagnosed with acute optic neuritis. It will also explore how the body absorbs and breaks down the study drug, and what effects it has on the immune system.

Clinical Trial Description

Oral lipoic acid is an antioxidant that helps proteins work in the body. It is available in oral and intravenous formulations and has been used in the past to treat nerve damage like that seen in diabetes and some other metabolic disorders. It is available as a dietary supplement in the United States.

Patients with a diagnosis of acute optic neuritis who are enrolled in the study will undergo medical and nervous system examinations, and blood draws. The study doctor will take a medical history and perform physical examinations. Research assistants at the MS Center, who are trained in blood draws, will perform the blood draws. Patients will also undergo Optical coherence tomography (OCT) examination at Casey Eye Institute, and receive two MRIs at Oregon Health and Science University (OHSU). Because it is a placebo-controlled trial, subjects will have a 50:50 chance of receiving either placebo (inactive) or study drug. If enrolled in the study, patients will take two gel capsules of the study drug or placebo at the same time every day for six weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01294176
Study type	Interventional
Source	Oregon Health and Science University
Contact
Status	Completed
Phase	Phase 1
Start date	January 2011
Completion date	November 2016

View Details

See also
Status	Clinical Trial	Phase
Unknown status	`NCT00261326` - Simvastatin Treatment of Patients With Acute Optic Neuritis	Phase 3
Active, not recruiting	`NCT03963310` - Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
Recruiting	`NCT03586557` - Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis	N/A
Recruiting	`NCT05487989` - VIsual Pathways Model in Neuro-inflammatory Disorders
Terminated	`NCT04131764` - Diagnosis of ON With or Without MS or NMOSD
Not yet recruiting	`NCT06453694` - Efgartigimod for the Treatment of Acute Optic Neuritis	Phase 2
Completed	`NCT01962571` - Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial	Phase 3
Recruiting	`NCT03302585` - High-Dose Vitamin D Induction in Optic Neuritis	Phase 2
Recruiting	`NCT02886377` - The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset	N/A
Completed	`NCT01987167` - Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis	Early Phase 1
Completed	`NCT01451593` - Neuroprotection With Phenytoin in Optic Neuritis	Phase 2
Completed	`NCT03630497` - BN201 SAD MAD Study in Healthy Subjects	Phase 1
Completed	`NCT01337986` - Ampyra for Optic Neuritis in Multiple Sclerosis	Phase 2/Phase 3
Completed	`NCT01274702` - Visual Reconstitution Therapy After Optic Neuritis	Phase 2
Active, not recruiting	`NCT00445367` - Biobank For MS And Other Demyelinating Diseases
Withdrawn	`NCT00037115` - Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.	Phase 4
Not yet recruiting	`NCT06389968` - Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis	N/A
Recruiting	`NCT04257734` - Epidemiologic and Clinical Characteristics of Optic Neuritis in China
Completed	`NCT03753893` - Ocular Manifestations in Rheumatic Diseases
Completed	`NCT02939937` - Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis	Phase 2